

Rhodium(III)-Catalyzed Regioselective C–H Alkenylation of Phenylphosphine Sulfides


Yuki Yokoyama,[†] Yuto Unoh,[†] Koji Hirano,[†] Tetsuya Satoh,^{*,†,‡} and Masahiro Miura^{*,†}

[†]Department of Applied Chemistry, Faculty of Engineering, Osaka University, Suita, Osaka 565-0871, Japan

[‡]JST, ACT-C, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan

S Supporting Information


ABSTRACT: The regioselective alkenylation at the *ortho* position of phenylphosphine sulfides using alkenes proceeds efficiently in the presence of a cationic Cp^{*}-rhodium(III) catalyst and an appropriate oxidant. A similar rhodium catalyst also promotes the redox-neutral coupling of the phosphine sulfides with alkynes to afford *ortho*-alkenylated products.



INTRODUCTION

The direct C–H functionalization reactions of arenes and heteroarenes under transition-metal catalysis have attracted much attention as powerful synthetic tools because they provide atom- and step-economical routes to target molecules from readily available substrates without preactivation by halogenation or metalation.¹ Among such useful transformations, catalytic dehydrogenative alkenylation using alkenes in the presence of a palladium catalyst and an oxidant, known as the Fujiwara–Moritani reaction,² has been developed and utilized in the synthesis of π -conjugated alkenylarene molecules. However, in this reaction there is a substantial problem of forming mixtures of regioisomers of alkenylarenes. This can be overcome by utilizing a directing group, which is capable of inducing regioselective C–H alkenylation at the proximate positions. As such directing groups, oxygen- and nitrogen-containing substituents including carboxyl, hydroxy, amide, and pyridyl functions have been widely employed.¹ In addition, phosphorus-containing groups such as phosphinoxy and phosphine oxide groups have been recently shown to be applicable. As leading examples, Kim and Lee's and Moon's groups (using palladium catalyst)³ and we (using rhodium or ruthenium catalyst)^{4,5} reported P–OH or P=O group-directed regioselective functionalization. In the context of our continuous studies on rhodium catalysis,^{1t} we succeeded in finding that phenylphosphine sulfides also undergo catalytic alkenylation through C–H bond cleavage directed by their P=S group to produce *ortho*-alkenylated phenylphosphine sulfides (Scheme 1). Such *ortho*-substituted phenylphosphine sulfides have recently attracted attention because of their applicability as soft and flexible ligands for transition metals.⁶ In addition, a relevant *ortho*-alkenylation using internal alkynes in the presence of a similar catalyst system is also disclosed herein.

Scheme 1. Rhodium-Catalyzed Regioselective Alkenylation




RESULTS AND DISCUSSION

In an initial attempt, dicyclohexyl(phenyl)phosphine sulfide (**1a**) (0.25 mmol) was treated with butyl acrylate (**2a**) (2 mmol) under conditions similar to those for the reaction of phenylphosphine oxides,^{4a} in the presence of [Cp^{*}Rh(MeCN)₃][SbF₆]₂ (0.01 mmol) and AgOAc (1 mmol) in *o*-dichlorobenzene (3 mL) at 120 °C for 6 h under N₂. In contrast to the oxides, sulfide **1a** did not undergo alkenylation smoothly. Thus, only a trace amount of desired product, butyl (*E*)-3-[2-(dicyclohexylphosphorothioyl)phenyl]acrylate (**3a**), was formed (entry 1 in Table 1). One of reasons for the failure is likely due to the thiophilicity of silver. Expectedly, the use of Cu(OAc)₂·H₂O (0.5 mmol) in place of AgOAc significantly improved the reaction efficiency to give **3a** in 50% yield (entry 2). It was confirmed that the reaction did not proceed at all in the absence of the rhodium catalyst (entry 3). The use of cationic [Cp^{*}Rh(MeCN)₃][SbF₆]₂ is essential for the reaction: electrically neutral [Cp^{*}RhCl₂]₂ did not promote the reaction effectively (entry 4). The yield of **3a** was enhanced to 60% in chlorobenzene (entry 5). The addition of 1,2,3,4-tetraphenyl- and 1,2,3,4,5-pentaphenyl-1,3-cyclopentadienes

Received: July 11, 2014

Published: July 30, 2014

Table 1. Reaction of Dicyclohexyl(phenyl)phosphine Sulfide (1a) with Butyl Acrylate (2a)^a


entry	additive	solvent	yield of 3a (%) ^b
1 ^c		<i>o</i> -C ₆ H ₄ Cl ₂	tr
2		<i>o</i> -C ₆ H ₄ Cl ₂	50
3 ^d		<i>o</i> -C ₆ H ₄ Cl ₂	0
4 ^e		<i>o</i> -C ₆ H ₄ Cl ₂	tr
5		C ₆ H ₅ Cl	60
6	C ₅ H ₂ Ph ₄ ^f	C ₆ H ₅ Cl	62
7	C ₅ HPh ₅ ^g	C ₆ H ₅ Cl	69
8	C ₅ HPh ₅ ^g	diglyme	74 (61)
9 ^h	C ₅ HPh ₅ ^g	diglyme	69 (58)


^aReaction conditions: **1a** (0.25 mmol), **2a** (2 mmol), [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol), additive (0.01 mmol), Cu(OAc)₂·H₂O (0.5 mmol), in solvent (3 mL) at 120 °C for 8 h under N₂, unless otherwise noted. ^bGC yield based on the amount of **1a** used. Value in parentheses indicates yield after purification. ^cUsing AgOAc (1 mmol) in place of Cu(OAc)₂·H₂O. ^dWithout [Cp*Rh(MeCN)₃][SbF₆]₂. ^eUsing [(Cp*RhCl₂)₂] (0.005 mmol) in place of [Cp*Rh(MeCN)₃][SbF₆]₂. ^fC₅H₂Ph₄ = 1,2,3,4-tetraphenyl-1,3-cyclopentadiene. ^gC₅HPh₅ = 1,2,3,4,5-pentaphenyl-1,3-cyclopentadiene. ^hWith **2a** (1 mmol).

(0.01 mmol) (C₅H₂Ph₄ and C₅HPh₅, respectively) slightly improved the **3a** yield (entries 6 and 7). This kind of Cp-ligand was previously employed for promoting rhodium-catalyzed oxidative coupling,⁷ although its exact role was not clear. With C₅HPh₅ in diglyme, the best yield of **3a** (74%) was obtained (entry 8). Under these conditions, a comparable yield was still achieved even when the amount of **2a** was reduced to 1 mmol (entry 9).

Under the optimized reaction conditions, the coupling reactions of a number of substituted phenyl- and naphthylphosphine sulfides with alkenes were next examined (Table 2). Treatment of **1a** with various acrylate esters **2b–e** gave the corresponding *ortho*-alkenylated phenylphosphine sulfides in moderate to good yields (entries 1–5). In some cases, contamination by trace amounts of *Z*-isomers was observed. In contrast, the reaction with an acrylamide **2g** afforded **3g** as a mixture of *2E*- and *2Z*-isomers (entry 6). It was found that styrene (**2h**) is less reactive than acrylic acid derivatives. However, the reaction of **1a** with **2h** proceeded by increasing the amount of Rh catalyst and extending the reaction time to 30 h to give the stilbene derivative **3h** (entry 7).

A series of *para*- and *meta*-substituted phenylphosphine sulfides **1b–h** underwent the coupling with **2a** to produce **3i–o** in 35–74% yields (entries 8–14). In the reaction of dicyclohexyl(2-naphthyl)phosphine sulfide (**1i**), alkenylation took place at the sterically less hindered position to afford a 3-alkenylated product **3p** selectively (entry 15). In addition to these aryldicyclohexylphosphine sulfides, diisopropyl(phenyl)phosphine sulfide (**1j**) also reacted with **2a** to give **3q** (entry 16).

A plausible mechanism for the reaction of phenylphosphine sulfide **1** with alkene **2** is illustrated in Scheme 2. Coordination of the P=S group^{6d} of **1** to a cationic Rh^{III} center and subsequent *ortho*-rhodation would occur to form a five-membered rhodacycle intermediate **A**. Then, alkene insertion to form **B** and β-hydrogen elimination may take place to

Table 2. Reaction of Phenylphosphine Sulfides **1** with Alkenes **2**^a



entry	1	2	product, % yield (<i>E</i> : <i>Z</i>) ^b
1			3b : R = CO ₂ Bu ⁱ , 60 (>99:1)
2			3c : R = CO ₂ Bu ⁱ , 73 (96:4)
3			3d : R = CO ₂ Cy, 65 (>99:1)
4			3e : R = CO ₂ Et, 42 (98:2)
5			3f : R = CO ₂ Ph, 30 (93:7)
6			3g : R = CONMe ₂ , 30 (74:26)
7 ^c			3h : R = Ph, 32 (96:4)
8			3i : R = Me, 48 (98:2)
9			3j : R = OMe, 35 (93:7)
10			3k : R = Cl, 38 (97:3)
11			3l : R = Me, 74 (>99:1)
12			3m : R = OMe, 57 (97:3)
13			3n : R = Ph, 74 (98:2)
14			3o : R = CF ₃ , 41 (93:7)
15			3p , 49 (97:3)
16			3q , 61 (97:3)

^aReaction conditions: **1** (0.25 mmol), **2** (1 mmol), [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol), C₅HPh₅ (0.01 mmol), Cu(OAc)₂·H₂O (0.5 mmol), in diglyme (3 mL) at 120 °C for 8 h under N₂, unless otherwise noted. ^bDetermined by ¹H NMR. ^cThe reaction was conducted with [Cp*Rh(MeCN)₃][SbF₆]₂ (0.02 mmol) in the absence of C₅HPh₅ for 30 h.

produce **3** involving H⁺ release. The resulting Rh^I species would be oxidized by Cu^{II} to regenerate Rh^{III}.




To obtain mechanistic insight, a deuterated substrate, dicyclohexyl(*d*₅-phenyl)phosphine sulfide (**1a-d₅**), was treated with **2a** under standard conditions (Scheme 3a). In the early stage, considerable contamination by protons at the *ortho* positions of recovered **1a-d_n** as well as at the 6-position of produced **3a-d_n** was observed. This result indicates that the initial C–H(D) bond cleavage step to form **A** is likely reversible. This is supported by the observed H–D exchange at the *ortho* positions of **1a** upon treatment with CD₃CO₂D in chlorobenzene in the presence of [Cp*Rh(MeCN)₃][SbF₆]₂ (Scheme 3b). Interestingly, the H–D exchange did not take

Scheme 2. Plausible Mechanism for the Reaction of 1 with 2



Scheme 3. Investigation for Mechanistic Insights

a. Reaction Using Deuterium-Labeled Substrate



b. Treatment Using CD₃CO₂D with Cationic Rh Speciesc. Treatment Using CD₃CO₂D with Neutral Rh Species

place at all in the presence of neutral Rh^{III} species such as [Cp*RhCl₂]₂ and Cp*Rh(OAc)₂ (Scheme 3c). Therefore, the use of a cationic Rh catalyst is essential to facilitate the C–H(D) bond cleavage step, while it is likely that other steps including alkene insertion can also be promoted by it.

It was found that alkenylation on an alkenyl C–H bond can be performed by utilizing the P=S directing group. Thus, treatment of dicyclohexyl(1-phenylethen-1-suppil)phosphine sulfide (4) (0.25 mmol) with 2a (1 mmol) in the presence of [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol), C₃HPh₅ (0.01 mmol), and Cu(OAc)₂·H₂O (0.5 mmol) in diglyme (3 mL) at 120 °C for 8 h under N₂ gave butyl (2*E*,4*Z*)-5-(dicyclohexylphosphorothioyl)-5-phenylpenta-2,4-dienoate (5) in a moderate yield (Scheme 4).

Recently, we^{7a,8} and other groups^{5c,9} reported the Cp*Rh^{III}-catalyzed *ortho*-alkenylation using alkynes as alkenyl source under redox-neutral conditions. Therefore, we applied the procedure to phenylphosphine sulfides. Expectedly, 1a (0.25 mmol) reacted with 1-phenyl-1-propyne (6a) (0.25 mmol) in

Scheme 4. Reaction of 4 with 2a

Table 3. Reaction of Dicyclohexyl(phenyl)phosphine Sulfide (1a) with 1-Phenyl-1-propyne (6a)^a

entry	additive	solvent	yield of 3a (%) ^b
1	AcOH	diglyme	32
2	AcOH	C ₆ H ₅ Cl	41
3	AcOH	<i>o</i> -C ₆ H ₄ Cl ₂	37
4	AcOH	DMF	14
5	AcOH	<i>o</i> -xylene	19
6	EtCO ₂ H	C ₆ H ₅ Cl	41
7	1-AdCO ₂ H	C ₆ H ₅ Cl	35
8	PivOH	C ₆ H ₅ Cl	32
9	2,6-Me ₂ C ₆ H ₃ CO ₂ H	C ₆ H ₅ Cl	25
10	CF ₃ CO ₂ H	C ₆ H ₅ Cl	8
11 ^c	AcOH	C ₆ H ₅ Cl	43
12 ^d	AcOH	C ₆ H ₅ Cl	53 (47)

^aReaction conditions: 1a (0.25 mmol), 6a (0.25 mmol), [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol), acid (1 mmol), in solvent (3 mL) at 120 °C for 3 h under N₂, unless otherwise noted. ^bGC yield based on the amount of 6a used. Value in parentheses indicates yield after purification. ^cAt 100 °C. ^dWith 1a (0.38 mmol).

the presence of [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol) and AcOH (1 mmol) in diglyme (3 mL) at 120 °C under N₂ to produce dicyclohexyl(2-(1-phenylprop-1-en-2-yl)phenyl)phosphine sulfide (7a) in 32% yield (entry 1 in Table 3). Chlorobenzene was found to be the solvent of choice among those examined (entries 1–5). The selection of acid was also important. EtCO₂H was as effective as AcOH (entry 6), although 1-adamantanecarboxylic acid, pivalic acid, 2,6-dimethylbenzoic acid, and trifluoroacetic acid were less effective (entries 7–10). At 100 °C, a similar result was obtained (entry 11). Finally, the use of a slightly excess amount of 1a (1.5 equiv) increased the yield of 7a to 53% (entry 12). The NMR spectra for 7a isolated in entry 12 showed that the alkenyl moiety of the product has *E* geometry (*E*/*Z* = >99:1).

The *ortho*-alkenylations of 1a with other alkynes 6 were next examined. Unsubstituted and substituted diphenylacetylene 6b–e reacted with 1a under similar conditions to afford products 7b–e (entries 1–4 in Table 4). In the cases with 6b and 6c, only the *E*-isomer of 7 was obtained selectively. The reactions of unsymmetrical alkynes 6f and 6g proceeded regioselectively to produce 7f and 7g in moderate yields (entries 5 and 6).


The *ortho*-alkenylation of 1a with alkynes 6 seems to proceed through a common rhodacycle intermediate A in Scheme 2. Alkyne insertion into the C–Rh bond in A and subsequent protonolysis by AcOH may occur to produce 7 accompanied by regeneration of an active Rh^{III} species (Scheme 5).

Table 4. Reaction of 1a with Alkynes 6^a

entry	6	product, % yield (<i>E:Z</i>) ^b
1	6b : Ar = Ph	7b : Ar = Ph, 37 (>99:1)
2	6c : Ar = 4-ClC ₆ H ₄	7c : Ar = 4-ClC ₆ H ₄ , 27 (>99:1)
3	6d : Ar = 4-MeOC ₆ H ₄	7d : Ar = 4-MeOC ₆ H ₄ , 13 (85:15)
4	6e : Ar = 4-MeC ₆ H ₄	7e : Ar = 4-MeC ₆ H ₄ , 13 (76:24)
5	6f : R = Bu	7f : R = Bu, 29 (97:3)
6	6g : R = (CH ₂) ₄ Cl	7g : R = (CH ₂) ₄ Cl, 23 (93:7)

^aReaction conditions: 1a (0.38 mmol), 6 (0.25 mmol), [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol), AcOH (1 mmol), in chlorobenzene (3 mL) at 120 °C for 3 h under N₂. ^bDetermined by ¹H NMR.

Scheme 5. Possible Pathway for the Reaction of 1a with 6



CONCLUSIONS

We have demonstrated that the rhodium-catalyzed *ortho*-alkenylation of phenylphosphine sulfides takes place through P=S group-directed C–H bond cleavage. The *ortho*-alkenylated phenylphosphine sulfides can also be prepared via the redox-neutral coupling with alkynes.

EXPERIMENTAL SECTION

General. ¹H and ¹³C NMR spectra were recorded at 400 and 100 MHz for CDCl₃ solutions. HRMS data were obtained by EI using a double focusing mass spectrometer, unless noted otherwise. GC analysis was carried out using a silicon OV-17 column (i.d. 2.6 mm × 1.5 m). GC–MS analysis was carried out using a CBP-1 capillary column (i.d. 0.25 mm × 25 m). The structures of all products listed below were unambiguously determined by ¹H and ¹³C NMR with the aid of NOE, COSY, HMQC, and HMBC experiments.

Phosphine sulfides 1a–j and 4^{10,11} and alkynes 6b–e¹² and 6g¹³ were prepared according to published procedures. All starting materials and reagents were commercially available.

General Procedure for the Reaction of Phenylphosphine Sulfides with Alkenes. To a 20 mL two-necked flask with a reflux condenser, a balloon, and a rubber cup were added phenylphosphine sulfide 1 (0.25 mmol), alkene 2 (1 mmol), [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol, 8 mg), C₅HPh₂ (0.01 mmol, 5 mg), Cu(OAc)₂·H₂O (0.5 mmol, 100 mg), dibenzyl (ca. 30 mg) as internal standard, and diglyme (3 mL). Then, the resulting mixture was stirred under nitrogen at 120 °C for 8 h. After cooling, the reaction mixture was extracted with ethyl acetate (100 mL). The organic layer was washed by water (100 mL, three times) and dried over Na₂SO₄. After evaporation of the solvent

under vacuum, product 3 was isolated by column chromatography on silica gel using hexane/ethyl acetate (20:1, v/v) as eluent.

General Procedure for the Reaction of Phenylphosphine Sulfides with Alkynes. To a 20 mL two-necked flask with a reflux condenser, a balloon, and a rubber cup were added phenylphosphine sulfide 1 (0.38 mmol), alkyne 6 (0.25 mmol), [Cp*Rh(MeCN)₃][SbF₆]₂ (0.01 mmol, 8 mg), AcOH (1 mmol, 57 μL), dibenzyl (ca. 30 mg) as internal standard, and chlorobenzene (3 mL). Then, the resulting mixture was stirred under nitrogen at 120 °C for 3 h. After cooling, the reaction mixture was extracted with ethyl acetate (100 mL). The organic layer was washed by water (100 mL, three times) and dried over Na₂SO₄. After evaporation of the solvent under vacuum, product 7 was isolated by column chromatography on silica gel using hexane/ethyl acetate (20:1, v/v) as eluent. Further purification by gel permeation chromatography (GPC) was performed, if needed.

Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)acrylate (3a). Colorless oil, 66 mg (61%); hexane/ethyl acetate 95:5 (v/v, eluent); ¹H NMR (400 MHz, CDCl₃) δ 0.99 (t, J = 7.3 Hz, 3H), 1.08–2.43 (m, 26H), 4.27 (t, J = 6.5 Hz, 2H), 6.29 (d, J = 15.5 Hz, 1H), 7.47–7.60 (m, 3H), 8.36 (d, J = 15.5 Hz, 1H), 8.39–8.47 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.7, 19.2, 25.5 (d, J = 1.5 Hz), 26.32 (d, J = 1.5 Hz), 26.33 (d, J = 2.3 Hz), 26.5 (d, J = 13.3 Hz), 27.4 (d, J = 2.2 Hz), 30.7, 39.7 (d, J = 48.6 Hz), 64.3, 121.6, 127.8 (d, J = 8.7 Hz), 128.5 (d, J = 62.2 Hz), 129.4 (d, J = 11.3 Hz), 131.3 (d, J = 11.2 Hz), 136.4 (d, J = 9.8 Hz), 137.1 (d, J = 5.9 Hz), 143.5 (d, J = 2.2 Hz), 166.2; ³¹P{¹H} NMR (162 MHz, CDCl₃) δ 64.7; HRMS *m/z* calcd for C₂₅H₃₈O₂PS (M + H⁺) 433.2325, found 433.2331.

Isobutyl (E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)acrylate (3b). Colorless oil, 65 mg (60%); hexane/ethyl acetate 95:5 (v/v, eluent); ¹H NMR (400 MHz, CDCl₃) δ 1.03 (d, J = 6.7 Hz, 6H), 1.09–2.43 (m, 23H), 4.06 (d, J = 6.5 Hz, 2H), 6.30 (d, J = 15.6 Hz, 1H), 7.47–7.63 (m, 3H), 8.33–8.48 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 19.2, 25.6 (d, J = 1.2 Hz), 26.36 (d, J = 13.5 Hz), 26.37 (d, J = 2.7 Hz), 26.5 (d, J = 13.8 Hz), 27.4 (d, J = 2.1 Hz), 27.9, 39.8 (d, J = 48.5 Hz), 71.0, 121.6, 127.9 (d, J = 8.5 Hz), 128.6 (d, J = 60.3 Hz), 129.4 (d, J = 11.2 Hz), 131.5 (d, J = 2.7 Hz), 136.4 (d, J = 9.5 Hz), 137.2 (d, J = 6.1 Hz), 143.5 (d, J = 2.3 Hz), 166.2; ³¹P{¹H} NMR (162 MHz, CDCl₃) δ 64.5; HRMS *m/z* calcd for C₂₅H₃₈O₂PS (M + H⁺) 433.2325, found 433.2351.

tert-Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)acrylate (3c). (*E:Z* = 96:4) Yellow oil, 79 mg (73%); hexane/ethyl acetate 95:5 (v/v, eluent); ¹H NMR (400 MHz, CDCl₃) δ 1.09–1.41 (m, 10H), 1.58 (s, 9H), 1.61–2.43 (m, 12H), 6.02 (d, J = 12.0 Hz, 1H, Z), 6.19 (d, J = 15.5 Hz, 1H), 7.40–7.63 (m, 3H), 8.23 (d, J = 15.5 Hz, 1H), 8.38–8.55 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 25.6 (d, J = 1.5 Hz), 26.4 (d, J = 3.0 Hz), 26.5 (d, J = 13.2 Hz), 26.6 (d, J = 13.9 Hz), 27.5 (d, J = 2.5 Hz), 28.2, 39.8 (d, J = 48.4 Hz), 81.0, 123.8, 127.7 (d, J = 8.6 Hz), 128.4 (d, J = 60.5 Hz), 129.2 (d, J = 11.3 Hz), 131.4 (d, J = 2.5 Hz), 136.7 (d, J = 10.0 Hz), 137.2 (d, J = 5.8 Hz), 142.7 (d, J = 2.5 Hz), 165.3; ³¹P{¹H} NMR (162 MHz, CDCl₃) δ 63.5 (Z), 64.8 (E); HRMS *m/z* calcd for C₂₅H₃₈O₂PS (M + H⁺) 433.2325, found 433.2328.

Cyclohexyl (E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)acrylate (3d). Pale yellow oil, 65 mg (65%); hexane/ethyl acetate 95 (v/v, eluent); ¹H NMR (400 MHz, CDCl₃) δ 1.07–2.45 (m, 32H), 4.98 (tt, J = 3.5, 8.6 Hz, 1H), 6.29 (d, J = 15.6 Hz, 1H), 7.47–7.63 (m, 3H), 8.36 (d, J = 15.5 Hz, 1H), 8.40–8.50 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 23.5, 25.4, 25.6 (d, J = 1.0 Hz), 26.38 (d, J = 2.5 Hz), 26.39 (d, J = 13.0 Hz), 26.5 (d, J = 13.0 Hz), 27.5 (d, J = 2.0 Hz), 31.6, 39.8 (d, J = 48.5 Hz), 72.9, 122.2, 127.7 (d, J = 8.5 Hz), 128.5 (d, J = 60.5 Hz), 129.4 (d, J = 11.1 Hz), 131.5 (d, J = 2.7 Hz), 136.5 (d, J = 9.5 Hz), 137.1 (d, J = 6.5 Hz), 143.2 (d, J = 2.8 Hz), 165.6; ³¹P{¹H} NMR (162 MHz, CDCl₃) δ 64.7; HRMS *m/z* calcd for C₂₇H₄₀O₂PS (M + H⁺) 459.2481, found 459.2495.

Ethyl (E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)acrylate (3e). (*E:Z* = 98:2) Yellow oil, 42 mg (42%); hexane/ethyl acetate 95:5 (v/v, eluent); ¹H NMR (400 MHz, CDCl₃) δ 1.09–2.44 (m, 25H), 4.32 (q, J = 7.1 Hz, 2H), 6.11 (d, J = 12.0 Hz, 1H, Z), 6.29 (d, J = 15.5 Hz, 1H), 7.48–7.63 (m, 3H), 8.370 (d, J = 15.6 Hz, 1H),

8.371–8.48 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 14.3, 25.6 (d, J = 1.4 Hz), 26.3 (d, J = 11.7 Hz), 26.4 (d, J = 2.9 Hz), 26.5 (d, J = 11.6 Hz), 27.4 (d, J = 2.8 Hz), 39.8 (d, J = 48.6 Hz), 60.8, 121.6, 127.9 (d, J = 8.5 Hz), 128.6 (d, J = 60.2 Hz), 129.4 (d, J = 11.0 Hz), 131.5 (d, J = 2.5 Hz), 136.5 (d, J = 9.7 Hz), 137.2 (d, J = 6.6 Hz), 143.7 (d, J = 2.8 Hz), 166.3; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 64.7; HRMS m/z calcd for $\text{C}_{23}\text{H}_{34}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 405.2012, found 405.2024.

Phenyl (E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)acrylate (3f). (*E:Z* = 96:4) Yellow oil, 33 mg (30%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.08–1.42 (m, 10H), 1.58–1.78 (m, 6H), 1.80–1.91 (m, 2H), 2.00–2.11 (m, 2H), 2.23–2.42 (m, 2H), 6.30 (d, J = 11.9 Hz, 1H, Z), 6.49 (d, J = 15.5 Hz, 1H), 7.18–7.24 (m, 2H), 7.28–7.31 (m, 1H), 7.40–7.48 (m, 2H), 7.52–7.61 (m, 2H), 7.62–7.72 (m, 2H), 8.32–8.45 (m, 1H), 8.65 (d, J = 15.5 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.6 (d, J = 1.0 Hz), 26.39 (d, J = 13.5 Hz), 26.41 (d, J = 2.7 Hz), 26.5 (d, J = 13.9 Hz), 27.2 (d, J = 2.6 Hz), 39.8 (d, J = 48.6 Hz), 120.3, 121.5, 126.0, 128.1 (d, J = 8.7 Hz), 128.8 (d, J = 59.4 Hz), 129.5, 129.8 (d, J = 11.1 Hz), 131.5 (d, J = 2.4 Hz), 136.3 (br), 137.1 (br), 145.8 (d, J = 2.8 Hz), 150.7, 164.9; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 61.7 (Z), 64.2 (E); HRMS m/z calcd for $\text{C}_{27}\text{H}_{34}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 453.2012, found 453.2011.

(E)-3-(2-(Dicyclohexylphosphorothioyl)phenyl)-*N,N*-dimethylacrylamide (3g). (*E:Z* = 74:26) Yellow oil, 30 mg (30%); hexane/ethyl acetate 50:50 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.10–1.63 (m, 13H), 1.65–2.13 (m, 7H), 2.23–2.39 (m, 2H, Z), 2.39–2.51 (m, 2H, E), 2.88 (s, 3H, Z), 2.90 (s, 3H, Z), 3.12 (s, 3H, E), 3.20 (s, 3H, E), 6.20 (d, J = 12.3 Hz, 1H, Z), 6.72 (d, J = 14.9 Hz, 1H, E), 7.36–7.43 (m, 3H, Z), 7.47–7.55 (m, 3H, E), 7.50 (d, J = 11.5 Hz, 1H, Z), 7.83–7.97 (m, 1H, Z), 8.16 (d, J = 15.0 Hz, 1H, E), 8.48–8.70 (m, 1H, E); ^{13}C NMR (100 MHz, CDCl_3) δ 25.59 (d, J = 1.3 Hz, E), 25.64 (d, J = 1.3 Hz, Z), 26.1 (br, Z), 26.2 (d, J = 13.6 Hz, E), 26.41 (d, J = 13.1 Hz, overlapped, Z), 26.43 (d, J = 2.6 Hz, E), 26.5 (d, J = 13.6 Hz, overlapped), 27.7 (d, J = 2.3 Hz, E), 34.5 (Z), 36.0 (E), 37.4 (E), 37.7 (Z), 39.4 (d, J = 48.2 Hz, E), 39.9 (d, J = 49.1 Hz, Z), 121.5 (E), 124.1 (Z), 125.8 (d, J = 62.7 Hz, Z), 127.7 (d, J = 5.7 Hz, E), 127.8 (d, J = 10.6 Hz, Z), 128.5 (d, J = 60.7 Hz, E), 128.9 (d, J = 11.3 Hz, E), 130.1 (d, J = 9.1 Hz, Z), 131.1 (d, J = 2.6 Hz, Z), 131.3 (d, J = 2.6 Hz, E), 133.5 (br, Z), 134.8 (d, J = 2.9 Hz, Z), 137.1 (d, J = 10.3 Hz, E), 137.9 (d, J = 6.5 Hz, E), 140.5 (br, Z), 141.6 (d, J = 2.0 Hz, E), 165.8 (E), 168.1 (Z); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 60.8 (Z), 66.3 (E); HRMS m/z calcd for $\text{C}_{23}\text{H}_{35}\text{NOPS}$ ($\text{M} + \text{H}^+$) 404.2171, found 404.2175.

(E)-Dicyclohexyl(2-styrylphenyl)phosphine Sulfide (3h). (*E:Z* = 93:7) Yellow oil, 33 mg (32%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.06–1.51 (m, 10H), 1.58–2.46 (m, 12H), 6.73 (d, J = 12.3 Hz, 1H, Z), 6.90 (d, J = 15.9 Hz, 1H), 7.29–7.66 (m, 8H), 7.94 (d, J = 15.6 Hz, 1H), 8.22 (dd, J = 7.8, 14.1 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.6 (br), 26.4 (d, J = 2.7 Hz), 26.5 (d, J = 6.5 Hz), 26.6 (d, J = 6.5 Hz), 27.0 (d, J = 2.0 Hz), 39.4 (d, J = 48.9 Hz), 126.4 (d, J = 63.0 Hz), 127.0, 127.2 (d, J = 11.2 Hz), 127.9 (d, J = 9.0 Hz), 128.0 (d, J = 3.9 Hz), 128.2, 129.0, 131.4 (d, J = 2.7 Hz), 132.2, 135.3, 137.1, 141.2 (d, J = 5.8 Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 63.2 (E), 65.7 (Z); HRMS m/z calcd for $\text{C}_{26}\text{H}_{34}\text{PS}$ ($\text{M} + \text{H}^+$) 409.2113, found 409.2137.

Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)-5-methylphenyl)acrylate (3i). (*E:Z* = 98:2) Colorless oil, 54 mg (48%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.98 (t, J = 7.4 Hz, 3H), 1.07–2.38 (m, 26H), 2.41 (s, 3H), 4.26 (t, J = 6.5 Hz, 2H), 6.09 (d, J = 12.0 Hz, 1H, Z), 6.28 (d, J = 15.5 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 5.0 Hz, 1H), 8.29 (dd, J = 8.0, 14.1 Hz, 1H), 8.34 (d, J = 16.3 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 21.2, 25.6 (d, J = 1.2 Hz), 26.39 (d, J = 2.6 Hz), 26.40 (d, J = 13.8 Hz), 26.5 (d, J = 13.8 Hz), 27.4 (d, J = 2.1 Hz), 30.8, 40.5 (d, J = 48.8 Hz), 64.6, 121.4, 125.6 (d, J = 62.3 Hz), 128.7 (d, J = 8.9 Hz), 130.3 (d, J = 11.5 Hz), 136.7 (d, J = 9.5 Hz), 137.0 (d, J = 6.4 Hz), 141.9 (d, J = 2.6 Hz), 143.8 (d, J = 2.5 Hz), 166.4; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 64.1; HRMS m/z calcd for $\text{C}_{26}\text{H}_{40}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 447.2481, found 447.2485.

Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)-5-methoxyphenyl)acrylate (3j). (*E:Z* = 93:7) Pale yellow oil, 41 mg (35%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.98 (t, J = 7.4 Hz, 3H), 1.09–2.37 (m, 26H), 3.87 (s, 3H), 4.27 (t, J = 6.5 Hz, 2H), 6.10 (d, J = 12.0 Hz, 1H, Z), 6.27 (d, J = 15.5 Hz, 1H), 7.01 (dd, J = 2.5, 8.7 Hz, 1H), 7.06 (dd, J = 3.0, 3.1 Hz, 1H), 8.32 (d, J = 14.4 Hz, 1H), 8.35 (d, J = 13.5 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.7, 25.6 (br), 26.37 (d, J = 2.5 Hz), 26.39 (d, J = 14.1 Hz), 26.5 (d, J = 14.2 Hz), 27.4 (d, J = 2.1 Hz), 30.8, 39.8 (d, J = 49.3 Hz), 55.4, 64.7, 113.8 (d, J = 9.5 Hz), 114.2 (d, J = 12.2 Hz), 119.5 (d, J = 65.8 Hz), 121.8, 138.6 (br), 138.7, 143.6 (d, J = 2.0 Hz), 161.9 (d, J = 2.7 Hz), 166.2; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 61.8 (Z), 63.4 (E); HRMS m/z calcd for $\text{C}_{26}\text{H}_{40}\text{O}_3\text{PS}$ ($\text{M} + \text{H}^+$) 463.2430, found 463.2438.

Butyl (E)-3-(5-Chloro-2-(dicyclohexylphosphorothioyl)phenyl)acrylate (3k). (*E:Z* = 97:3) Colorless oil, 45 mg (38%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.99 (t, J = 7.4 Hz, 3H), 1.08–2.40 (m, 26H), 4.27 (t, J = 6.5 Hz, 2H), 6.15 (d, J = 12.0 Hz, 1H, Z), 6.31 (d, J = 15.6 Hz, 1H), 7.44–7.56 (m, 2H), 8.26 (d, J = 15.6 Hz, 1H), 8.39 (dd, J = 8.4, 13.7 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 25.5 (d, J = 1.1 Hz), 26.3 (d, J = 14.5 Hz), 26.4 (overlapped), 26.5 (d, J = 13.9 Hz), 27.4 (d, J = 2.1 Hz), 30.8, 39.8 (d, J = 48.7 Hz), 64.9, 122.9, 127.2 (d, J = 60.5 Hz), 127.7 (d, J = 9.0 Hz), 129.3 (d, J = 11.8 Hz), 138.1 (d, J = 3.4 Hz), 138.3 (d, J = 10.9 Hz), 138.6 (d, J = 7.0 Hz), 142.2 (d, J = 2.0 Hz), 165.9; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 64.7; HRMS m/z calcd for $\text{C}_{25}\text{H}_{37}\text{O}_2\text{ClPS}$ ($\text{M} + \text{H}^+$) 467.1935, found 467.1944.

Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)-4-methylphenyl)acrylate (3l). Colorless oil, 82 mg (74%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.99 (t, J = 7.4 Hz, 3H), 1.09–2.40 (m, 26H), 2.43 (s, 3H), 4.26 (t, J = 6.5 Hz, 2H), 6.28 (d, J = 15.5 Hz, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.48 (dd, J = 4.5, 7.8 Hz, 1H), 8.25 (d, J = 16.0 Hz, 1H), 8.29 (d, J = 16.2 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 21.5, 25.6 (d, J = 1.1 Hz), 26.4 (d, J = 13.9 Hz), 26.46 (d, J = 2.7 Hz), 26.54 (d, J = 13.8 Hz), 27.7 (d, J = 2.4 Hz), 30.8, 39.9 (d, J = 48.5 Hz), 64.6, 120.8, 127.7 (d, J = 8.9 Hz), 128.5 (d, J = 60.1 Hz), 132.2 (d, J = 2.6 Hz), 133.8 (d, J = 6.1 Hz), 137.4 (d, J = 10.0 Hz), 140.0 (d, J = 48.9 Hz), 143.3 (d, J = 42.2 Hz), 166.4; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 64.5; HRMS m/z calcd for $\text{C}_{26}\text{H}_{40}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 447.2481, found 447.2510.

Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)-4-methoxyphenyl)acrylate (3m). (*E:Z* = 97:3) Purple oil, 66 mg (57%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.99 (t, J = 7.4 Hz, 3H), 1.08–1.78 (m, 20H), 1.80–1.92 (m, 2H), 1.99–2.11 (m, 2H), 2.23–2.45 (m, 2H), 3.90 (s, 3H), 4.25 (t, J = 6.5 Hz, 2H), 6.07 (d, J = 11.9 Hz, 1H, Z), 6.24 (d, J = 15.4 Hz, 1H), 7.00 (dd, J = 2.0, 8.5 Hz, 1H), 7.56 (dd, J = 3.6, 5.0 Hz, 1H), 8.13 (dd, J = 2.6, 15.8 Hz, 1H), 8.19 (d, J = 15.5 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 25.6 (d, J = 1.2 Hz), 26.36 (d, J = 13.6 Hz), 26.40 (d, J = 3.1 Hz), 26.5 (d, J = 13.7 Hz), 27.8 (d, J = 2.3 Hz), 30.8, 40.1 (d, J = 48.2 Hz), 55.6, 64.6, 117.6 (d, J = 5.0 Hz), 119.3, 121.7 (d, J = 11.6 Hz), 128.7 (d, J = 6.3 Hz), 129.2 (d, J = 10.1 Hz), 131.1 (d, J = 58.8 Hz), 142.6 (d, J = 2.1 Hz), 160.6 (d, J = 13.3 Hz), 166.6; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 64.5 (Z), 66.4 (E); HRMS m/z calcd for $\text{C}_{26}\text{H}_{40}\text{O}_3\text{PS}$ ($\text{M} + \text{H}^+$) 463.2430, found 463.2442.

Butyl (E)-3-(3-(Dicyclohexylphosphorothioyl)-[1,1'-biphenyl]-4-yl)acrylate (3n). (*E:Z* = 98:2) Pale yellow oil, 95 mg (74%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.00 (d, J = 7.4 Hz, 3H), 1.11–2.48 (m, 26H), 4.28 (t, J = 6.5 Hz, 2H), 6.15 (d, J = 12.0 Hz, 1H, Z), 6.36 (d, J = 15.6 Hz, 1H), 7.36–7.80 (m, 7H), 8.35 (d, J = 15.6 Hz, 1H), 8.75 (d, J = 14.8 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 25.6 (br), 26.4 (d, J = 13.3 Hz), 26.5 (br), 26.6 (d, J = 13.3 Hz), 27.6 (d, J = 2.1 Hz), 30.8, 39.9 (d, J = 48.3 Hz), 64.7, 121.3, 127.1, 128.2, 128.3 (d, J = 9.0 Hz), 129.0, 129.3 (d, J = 58.9 Hz), 129.6 (d, J = 2.7 Hz), 135.3 (d, J = 11.1 Hz), 135.5 (d, J = 5.7 Hz), 139.2, 142.0 (d, J = 11.0 Hz), 143.0 (d, J = 2.3 Hz), 166.4; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 65.4; HRMS m/z calcd for $\text{C}_{31}\text{H}_{42}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 509.2638, found 509.2640.

Butyl (E)-3-(2-(Dicyclohexylphosphorothioyl)-4-(trifluoromethyl)phenyl)acrylate (3o). (*E:Z* = 93:7) Colorless oil, 52 mg

(41%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.99 (t, $J = 7.4$ Hz, 3H), 1.09–2.44 (m, 26H), 4.29 (t, $J = 6.6$ Hz, 2H), 6.20 (d, $J = 12.0$ Hz, 1H, Z), 6.36 (d, $J = 15.6$ Hz, 1H), 7.67 (dd, $J = 3.6, 8.0$ Hz, 1H), 7.75 (d, $J = 8.1$ Hz, 1H), 8.31 (d, $J = 15.6$ Hz, 1H), 8.75 (d, $J = 13.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 25.5 (d, $J = 1.4$ Hz), 26.3 (d, $J = 13.3$ Hz), 26.4 (d, $J = 3.0$ Hz), 26.5 (d, $J = 13.9$ Hz), 27.5 (d, $J = 2.1$ Hz), 30.8, 39.8 (d, $J = 48.3$ Hz), 65.0, 123.5 (q, $J = 271.1$ Hz), 123.7, 128.1–128.27 (m), 128.33 (d, $J = 8.2$ Hz), 130.5 (d, $J = 58.1$ Hz), 131.3 (dq, $J = 11.2, 33.1$ Hz), 133.3–133.6 (m), 140.5 (d, $J = 3.6$ Hz), 142.2 (d, $J = 1.4$ Hz), 165.8; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 63.7 (Z), 65.4 (E); HRMS m/z calcd for $\text{C}_{26}\text{H}_{37}\text{O}_2 \text{F}_3\text{PS}$ ($\text{M} + \text{H}^+$) 501.2198, found 501.2211.

Butyl (E)-3-(3-(Dicyclohexylphosphorothioyl)naphthalen-2-yl)acrylate (3p). (*E:Z* = 97:3) Mp 135–136 °C (pale yellow solid), 60 mg (49%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.00 (t, $J = 7.4$ Hz, 3H), 1.07–2.51 (m, 26H), 4.30 (t, $J = 6.5$ Hz, 2H), 6.23 (d, $J = 11.9$ Hz, 1H, Z), 6.43 (d, $J = 15.4$ Hz, 1H), 7.50–7.70 (m, 2H), 7.78–8.10 (m, 3H), 8.32 (d, $J = 15.4$ Hz, 1H), 9.06 (d, $J = 16.4$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.3, 25.6 (d, $J = 1.3$ Hz), 26.4 (d, $J = 14.3$ Hz), 26.5 (d, $J = 14.1$ Hz), 26.6 (d, $J = 2.5$ Hz), 28.0 (d, $J = 2.2$ Hz), 30.8, 39.9 (d, $J = 48.5$ Hz), 64.7, 121.7, 126.8 (d, $J = 61.1$ Hz), 127.69 (d, $J = 8.7$ Hz), 127.74, 127.9, 128.7, 129.1, 132.7 (d, $J = 12.3$ Hz), 132.8 (d, $J = 6.2$ Hz), 134.0 (d, $J = 2.2$ Hz), 139.5 (d, $J = 9.5$ Hz), 143.9, 166.3; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 65.2 (Z), 65.8 (E); HRMS m/z calcd for $\text{C}_{29}\text{H}_{40}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 483.2481, found 483.2497.

Butyl (E)-3-(2-(Diisopropylphosphorothioyl)phenyl)acrylate (3q). (*E:Z* = 97:3) Pale yellow oil, 53 mg (61%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.90 (dd, $J = 7.0, 18.1$ Hz, 6H), 0.99 (t, $J = 7.4$ Hz, 3H), 1.35 (dd, $J = 6.7, 17.5$ Hz, 6H), 1.47 (sext, $J = 7.3$ Hz, 2H), 1.72 (quin, $J = 6.6$ Hz, 2H), 2.55–2.72 (m, 2H), 4.25 (t, $J = 6.5$ Hz, 2H), 6.09 (d, $J = 12.0$ Hz, 1H, Z), 6.33 (d, $J = 15.5$ Hz, 1H), 7.49–7.64 (m, 3H), 8.40 (d, $J = 15.6$ Hz, 1H), 8.47 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 17.3 (d, $J = 1.9$ Hz), 17.7 (d, $J = 1.3$ Hz), 19.2, 29.8 (d, $J = 49.1$ Hz), 30.7, 64.8, 121.6, 127.9 (d, $J = 8.7$ Hz), 129.2 (d, $J = 60.9$ Hz), 129.5 (d, $J = 11.2$ Hz), 131.6 (d, $J = 2.4$ Hz), 136.3 (d, $J = 2.5$ Hz), 136.9 (d, $J = 7.1$ Hz), 143.1 (d, $J = 2.6$ Hz), 166.4; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 72.6; HRMS m/z calcd for $\text{C}_{16}\text{H}_{30}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 353.1699, found 353.1706.

Butyl (2E,4Z)-5-(Dicyclohexylphosphorothioyl)-5-phenylpenta-2,4-dienoate (5). Mp 143–144 °C (white solid), 30 mg (26%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.90 (t, $J = 7.4$ Hz, 3H), 1.08–2.12 (m, 27H), 4.09 (t, $J = 6.6$ Hz, 2H), 6.22 (d, $J = 15.4$ Hz, 1H), 7.04 (ddd, $J = 1.7, 11.5, 15.4$ Hz, 3H), 7.06–7.11 (m, 2H), 7.67 (dd, $J = 11.5, 19.3$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.7, 19.1, 25.8 (br), 26.1 (d, $J = 2.3$ Hz), 26.3 (d, $J = 3.1$ Hz), 26.48 (d, $J = 13.5$ Hz), 26.52 (d, $J = 13.3$ Hz), 30.6, 37.3 (d, $J = 49.7$ Hz), 64.5, 127.3, 128.6 (d, $J = 1.2$ Hz), 129.0, 129.2 (d, $J = 3.6$ Hz), 136.0 (d, $J = 7.4$ Hz), 138.4 (d, $J = 15.8$ Hz), 140.7 (d, $J = 55.6$ Hz), 144.4 (d, $J = 11.2$ Hz), 166.5; $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 63.5; HRMS m/z calcd for $\text{C}_{27}\text{H}_{40}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 459.2481, found 459.2508.

(E)-Dicyclohexyl(2-(1-phenylprop-1-en-2-yl)phenyl)phosphine Sulfide (7a). Mp 160–161 °C (white solid), 49 mg (47%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.09–2.00 (m, 20H), 2.29 (d, $J = 1.4$ Hz, 3H), 2.34–2.48 (m, 2H), 6.32 (s, 1H), 7.20–7.25 (m, 1H), 7.30–7.54 (m, 7H), 8.53 (ddd, $J = 1.4, 7.7, 14.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 22.0, 25.5 (br), 26.3 (d, $J = 12.9$ Hz), 26.5 (d, $J = 13.4$ Hz), 26.7 (br), 28.1 (br), 40.0 (d, $J = 48.6$ Hz), 126.90 (d, $J = 11.4$ Hz), 126.93 (d, $J = 63.6$ Hz), 127.2, 128.6, 128.7, 129.7 (d, $J = 9.3$ Hz), 130.1, 130.9 (d, $J = 2.7$ Hz), 136.5 (d, $J = 10.8$ Hz), 136.9, 138.5 (d, $J = 1.4$ Hz), 147.3 (d, $J = 7.4$ Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 68.1; HRMS m/z calcd for $\text{C}_{27}\text{H}_{36}\text{PS}$ ($\text{M} + \text{H}^+$) 423.2270, found 423.2287.

(E)-Dicyclohexyl(2-(1,2-diphenylvinyl)phenyl)phosphine Sulfide (7b). Mp 196–197 °C (gray solid), 45 mg (37%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.22–1.53 (m, 15H), 1.57–2.13 (m, 7H), 6.63 (s, 1H), 7.14–7.26 (m, 8H), 7.26–7.33 (m, 2H), 7.36–7.42 (m, 1H), 7.47–7.56 (m, 2H),

8.65 (ddd, $J = 1.9, 8.5, 15.2$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.4, 26.2 (br, overlapped), 26.4, 27.6 (d, $J = 2.6$ Hz), 37.8 (d, $J = 47.5$ Hz), 127.4, 127.6 (d, $J = 11.4$ Hz), 128.1 (d, $J = 61.4$ Hz), 128.2, 128.4, 128.7, 129.4, 130.2, 130.8 (d, $J = 2.7$ Hz), 131.5, 133.5 (d, $J = 9.4$ Hz), 136.7, 137.7 (d, $J = 11.6$ Hz), 138.7, 142.9 (d, $J = 2.6$ Hz), 144.4 (d, $J = 7.0$ Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 69.7; HRMS m/z calcd for $\text{C}_{32}\text{H}_{38}\text{PS}$ ($\text{M} + \text{H}^+$) 485.2426, found 485.2433.

(E)-(2-(1,2-Bis(4-chlorophenyl)vinyl)phenyl)dicyclohexylphosphine Sulfide (7c). Mp 192–193 °C (yellow solid), 37 mg (27%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.42–1.54 (m, 13H), 1.57–2.16 (m, 9H), 6.57 (s, 1H), 7.05–7.14 (m, 4H), 7.20–7.26 (m, 4H), 7.29–7.35 (m, 1H), 7.46–7.57 (m, 2H), 8.49–8.63 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.5, 26.4 (br, overlapped), 27.5 (d, $J = 2.1$ Hz), 38.3 (d, $J = 49.9$ Hz), 127.8 (d, $J = 11.2$ Hz), 128.2 (d, $J = 61.3$ Hz), 128.8, 129.0, 130.56, 130.61, 130.9 (d, $J = 2.7$ Hz), 131.6, 133.3, 133.4 (d, $J = 3.3$ Hz), 134.4, 134.8, 137.1, 137.3 (d, $J = 11.0$ Hz), 142.2 (d, $J = 1.4$ Hz), 144.4 (d, $J = 6.5$ Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 68.2; HRMS m/z calcd for $\text{C}_{32}\text{H}_{36}\text{Cl}_2\text{PS}$ ($\text{M} + \text{H}^+$) 553.1647, found 553.1646.

(E)-(2-(1,2-Bis(4-methoxyphenyl)vinyl)phenyl)dicyclohexylphosphine Sulfide (7d). (*E:Z* = 85:15) White solid, 18 mg (13%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.21–1.52 (m, 16H), 1.60–2.10 (m, 6H), 3.72 (s, 3H, Z), 3.81 (s, 6H, E), 3.83 (s, 3H, Z), 6.46 (s, 1H, E), 6.58–6.65 (m, 2H, Z), 6.74–6.84 (m, 4H, E), 6.88–6.94 (m, 2H, Z), 7.04–7.17 (m, 4H, E), 7.31–7.35 (m, 1H, E), 7.32–7.40 (m, 2H, Z), 7.44–7.53 (m, 2H, E), 7.53–7.60 (m, 2H, Z), 7.66–7.75 (m, 1H, Z), 8.56–8.69 (m, 1H, E), 8.69–8.79 (m, 1H, Z); ^{13}C NMR (100 MHz, CDCl_3) δ 24.5 (br), 25.4 (br, overlapped), 26.7 (d, $J = 2.6$ Hz), 36.6 (br), 54.2 (overlapped), 54.3 (E), 54.5 (Z), 112.6 (Z), 112.8 (E), 113.1 (E), 113.3 (Z), 126.3 (d, $J = 11.3$ Hz, E), 126.6 (d, $J = 11.2$ Hz, Z), 126.9 (Z), 127.1 (d, $J = 61.8$ Hz, E), 127.2 (d, $J = 60.1$ Hz, Z), 127.8 (Z), 127.9 (Z), 128.4 (E), 128.8 (E), 129.5 (Z), 129.6 (E), 129.7 (d, $J = 2.6$ Hz, E), 129.9 (E), 130.38 (E), 130.42 (Z), 130.6 (d, $J = 2.7$ Hz, Z), 132.2 (d, $J = 9.5$ Hz, Z), 132.4 (d, $J = 9.4$ Hz, E), 136.6 (d, $J = 10.8$ Hz, E), 137.1 (d, $J = 10.7$ Hz, Z), 137.9 (Z), 139.6 (E), 140.3 (d, $J = 6.5$ Hz, Z), 144.1 (d, $J = 7.1$ Hz, E), 157.7 (E), 158.0 (Z), 158.28 (Z), 158.33 (E); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 67.9 (Z), 69.7 (E); HRMS m/z calcd for $\text{C}_{34}\text{H}_{42}\text{O}_2\text{PS}$ ($\text{M} + \text{H}^+$) 545.2638, found 545.2636.

(E)-Dicyclohexyl(2-(1,2-di-p-tolylvinyl)phenyl)phosphine Sulfide (7e). (*E:Z* = 76:24) White solid, 17 mg (13%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.26–1.53 (m, 16H), 1.59–1.91 (m, 6H), 2.23 (s, 3H, Z), 2.33 (s, 3H, E), 2.35 (s, 3H, E), 2.38 (s, 3H, Z), 6.54 (s, 1H, E), 6.73–6.82 (m, 2H, Z), 6.82–6.94 (m, 1H, E), 7.00–7.12 (m, 6H), 7.15–7.23 (m, 1H), 7.31–7.40 (m, 1H), 7.44–7.59 (m, 2H), 8.59–8.68 (m, 1H, E), 8.68–8.79 (m, 1H, Z); ^{13}C NMR (100 MHz, CDCl_3) δ 21.2 (d, $J = 2.9$ Hz, Z), 21.4 (d, $J = 2.6$ Hz, E), 25.5 (br), 25.6 (br), 26.4 (br), 26.6 (br), 27.8 (br), 37.9 (br), 127.0 (Z), 127.5 (d, $J = 11.4$ Hz, E), 127.8 (d, $J = 11.3$ Hz, Z), 128.26 (d, $J = 61.6$ Hz, E), 128.31 (d, $J = 61.1$ Hz, Z), 129.1 (Z), 129.2 (E), 129.5 (E), 129.6 (E), 129.7 (Z), 129.8 (Z), 130.2 (E), 130.86 (d, $J = 2.7$ Hz, E), 130.93 (E), 131.0 (Z), 131.7 (d, $J = 2.7$ Hz, Z), 131.8 (Z), 133.27 (Z), 133.34 (d, $J = 3.4$ Hz, Z), 133.6 (d, $J = 9.4$ Hz, E), 134.1 (E), 136.2 (E), 137.4 (E), 137.75 (Z), 137.83 (d, $J = 10.7$ Hz, E), 138.15 (E), 138.24 (d, $J = 11.2$ Hz, Z), 140.7 (Z), 140.9 (d, $J = 1.6$ Hz, Z), 141.3 (d, $J = 6.8$ Hz, Z), 142.1 (d, $J = 1.4$ Hz, E), 145.1 (d, $J = 7.0$ Hz, E); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 69.9 (E), 68.0 (Z); HRMS m/z calcd for $\text{C}_{34}\text{H}_{42}\text{PS}$ ($\text{M} + \text{H}^+$) 513.2739, found 513.2737.

(E)-Dicyclohexyl(2-(1-phenylhex-1-en-2-yl)phenyl)phosphine Sulfide (7f). (*E:Z* = 97:3) Colorless oil, 34 mg (29%); hexane/ethyl acetate 95:5 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 0.82 (t, $J = 7.2$ Hz, 3H), 1.05–1.35 (m, 10H), 1.36–1.53 (m, 4H), 1.58–1.89 (m, 8H), 1.91–2.04 (m, 2H), 2.10–2.70 (m, 3H), 2.70–3.32 (br, 1H), 6.33 (s, 1H), 6.46 (s, 1H, Z), 7.15–7.22 (m, 1H), 7.28–7.34 (m, 1H), 7.37–7.49 (m, 6H), 8.45 (ddd, $J = 1.9, 7.3, 14.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.8, 23.0, 25.6 (d, $J = 1.2$ Hz), 26.3 (d, $J = 13.9$ Hz), 26.5 (d, $J = 13.6$ Hz), 26.7 (d, $J = 1.9$ Hz), 27.8 (br), 30.8, 34.1, 39.4 (d, $J = 48.7$ Hz), 126.8 (d, $J = 11.3$ Hz), 126.9 (d, $J = 63.5$ Hz), 127.0, 128.57, 128.60, 130.1, 130.5 (d, $J = 2.6$ Hz), 131.1 (d, $J =$

9.5 Hz), 136.0 (d, $J = 11.0$ Hz), 137.1, 143.8 (d, $J = 1.8$ Hz), 146.5 (d, $J = 7.6$ Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 67.3 (E), 69.6 (Z); HRMS m/z calcd for $\text{C}_{30}\text{H}_{42}\text{PS}$ ($\text{M} + \text{H}^+$) 465.2739, found 465.2754.

(E)-(2-(6-Chloro-1-phenylhex-1-en-2-yl)phenyl)dicyclohexylphosphine Sulfide (7g). ($E:Z = 93:7$) Pale yellow oil, 28 mg (23%); hexane/ethyl acetate 90:10 (v/v, eluent); ^1H NMR (400 MHz, CDCl_3) δ 1.07–1.36 (m, 9H), 1.38–1.50 (m, 2H), 1.50–1.55 (m, 1H), 1.59–1.76 (m, 8H), 1.79–1.87 (m, 2H), 1.92–2.07 (m, 2H), 2.18–2.61 (m, 3H), 2.75–3.19 (m, 1H), 3.34–3.48 (m, 2H), 6.36 (s, 1H), 6.44 (s, 1H, Z), 7.17–7.23 (m, 1H), 7.27–7.33 (m, 1H), 7.38–7.51 (m, 6H), 8.28 (ddd, $J = 1.4, 7.6, 13.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.6 (br), 25.7, 26.4 (d, $J = 13.4$ Hz), 26.5 (d, $J = 13.4$ Hz), 26.6 (br), 27.5 (br), 32.6, 33.7, 39.6 (d, $J = 48.4$ Hz), 44.5, 126.8 (d, $J = 11.3$ Hz), 126.9 (d, $J = 63.7$ Hz), 127.0, 128.57, 128.59, 130.4, 130.5 (d, $J = 2.7$ Hz), 131.4 (d, $J = 9.3$ Hz), 135.1 (d, $J = 10.4$ Hz), 137.1, 143.1 (d, $J = 2.2$ Hz), 147.0 (d, $J = 7.3$ Hz); $^{31}\text{P}\{^1\text{H}\}$ NMR (162 MHz, CDCl_3) δ 60.7 (Z), 65.3 (E); HRMS m/z calcd for $\text{C}_{30}\text{H}_{41}\text{ClPS}$ ($\text{M} + \text{H}^+$) 499.2350, found 499.2360.

■ ASSOCIATED CONTENT

Supporting Information

Copies of ^1H and ^{13}C NMR spectra of products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Authors

*E-mail: satoh@chem.eng.osaka-u.ac.jp.

*E-mail: miura@chem.eng.osaka-u.ac.jp.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was supported by Grants-in-Aid from MEXT, JSPS, and JST, Japan.

■ REFERENCES

(1) Selected recent reviews for C–H functionalization: (a) Jin, T.; Zhao, J.; Asao, N.; Yamamoto, Y. *Chem.—Eur. J.* **2014**, *20*, 3554. (b) De Sarkar, S.; Liu, W.; Kozhushkov, S. I.; Ackermann, L. *Adv. Synth. Catal.* **2014**, *356*, 1461. (c) Kuhl, N.; Schröder, N.; Glorius, F. *Adv. Synth. Catal.* **2014**, *356*, 1443. (d) Shi, G.; Zhang, Y. *Adv. Synth. Catal.* **2014**, *356*, 1419. (e) Bonin, H.; Sauthier, M.; Felpin, F.-X. *Adv. Synth. Catal.* **2014**, *356*, 645. (f) Engle, K. M.; Yu, J.-Q. *J. Org. Chem.* **2013**, *78*, 8927. (g) Wencel-Delord, J.; Glorius, F. *Nat. Chem.* **2013**, *5*, 369. (h) Colby, D. A.; Tsai, A. S.; Bergman, R. G.; Ellman, J. A. *Acc. Chem. Res.* **2012**, *45*, 814. (i) Engle, K. M.; Mei, T.-S.; Wasa, M.; Yu, J.-Q. *Acc. Chem. Res.* **2012**, *45*, 788. (j) Mitchell, E. A.; Peschiulli, A.; Lefevre, N.; Meerpoel, L.; Maes, B. U. W. *Chem.—Eur. J.* **2012**, *18*, 10092. (k) Cho, S. H.; Kim, J. Y.; Kwak, J.; Chang, S. *Chem. Soc. Rev.* **2011**, *40*, 5068. (l) Wencel-Delord, J.; Droge, T.; Liu, F.; Glorius, F. *Chem. Soc. Rev.* **2011**, *40*, 4740. (m) Kuninobu, Y.; Takai, K. *Chem. Rev.* **2011**, *111*, 1938. (n) Liu, C.; Zhang, H.; Shi, W.; Lei, A. *Chem. Rev.* **2011**, *111*, 1780. (o) Ackermann, L. *Chem. Rev.* **2011**, *111*, 1315. (p) Lapointe, D.; Fagnou, K. *Chem. Lett.* **2010**, *39*, 1118. (q) Lyons, T. W.; Sanford, M. S. *Chem. Rev.* **2010**, *110*, 1147. (r) Colby, D. A.; Bergman, R. G.; Ellman, J. A. *Chem. Rev.* **2010**, *110*, 624. (s) Sun, C.-L.; Li, B.-J.; Shi, Z.-J. *Chem. Commun.* **2010**, *46*, 677. (t) Satoh, T.; Miura, M. *Chem.—Eur. J.* **2010**, *16*, 11212. (u) Satoh, T.; Miura, M. *Synthesis* **2010**, 3395. (v) Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. *Angew. Chem., Int. Ed.* **2009**, *48*, 5094. (w) Daugulis, O.; Do, H.-Q.; Shabashov, D. *Acc. Chem. Res.* **2009**, *42*, 1074. (x) McGlacken, G. P.; Bateman, L. M. *Chem. Soc. Rev.* **2009**, *38*, 2447. (y) Li, C.-J. *Acc. Chem. Res.* **2009**, *42*, 335. (z) Kakiuchi, F.; Kochi, T. *Synthesis* **2008**, 3013. (aa) Ferreira, E. M.; Zhang, H.; Stoltz, B. M. *Tetrahedron* **2008**, *64*, 5987. (bb) Park, Y. J.; Park, J.-W.; Jun, C.-H. *Acc. Chem. Res.* **2008**, *41*, 222. (cc) Beccalli, E. M.; Brogini, G.; Martinelli, M.; Sottocornola, S. *Chem. Rev.* **2007**, *107*, 5318. (dd) Alberico, D.; Scott, M. E.; Lautens,

M. *Chem. Rev.* **2007**, *107*, 174. (ee) Godula, K.; Sames, D. *Science* **2006**, *312*, 67. (ff) Kakiuchi, F.; Chatani, N. *Adv. Synth. Catal.* **2003**, *345*, 1077. (gg) Dyker, G. *Angew. Chem., Int. Ed.* **1999**, *38*, 1698.

(2) For pioneering work, see: (a) Moritani, I.; Fujiwara, Y. *Tetrahedron Lett.* **1967**, *8*, 1119. (b) Fujiwara, Y.; Moritani, I.; Danno, S.; Asano, R.; Teranishi, S. *J. Am. Chem. Soc.* **1969**, *91*, 7166.

(3) Pd: (a) Chan, L. Y.; Meng, X.; Kim, S. *J. Org. Chem.* **2013**, *78*, 8826. (b) Chary, B. C.; Kim, S.; Park, Y.; Kim, J.; Lee, P. H. *Org. Lett.* **2013**, *15*, 2692. (c) Chan, L. Y.; Cheong, L.; Kim, S. *Org. Lett.* **2013**, *15*, 2186. (d) Jeon, W. H.; Lee, T. S.; Kim, E. J.; Moon, B.; Kang, J. *Tetrahedron* **2013**, *69*, 5152. (e) Meng, X.; Kim, S. *Org. Lett.* **2013**, *15*, 1910. (f) Chan, L. Y.; Kim, S.; Ryu, T.; Lee, P. H. *Chem. Commun.* **2013**, *49*, 4682.

(4) Rh: (a) Unoh, Y.; Hashimoto, Y.; Takeda, D.; Hirano, K.; Satoh, T.; Miura, M. *Org. Lett.* **2013**, *15*, 3258. Ru: (b) Itoh, M.; Hashimoto, Y.; Hirano, K.; Satoh, T.; Miura, M. *J. Org. Chem.* **2013**, *78*, 8098.

(5) Just after the leading publications, other groups also reported similar Rh- and Ru-catalyzed reactions: (a) Seo, J.; Park, Y.; Jeon, I.; Ryu, T.; Park, S.; Lee, P. H. *Org. Lett.* **2013**, *15*, 3358. (b) Chary, B. C.; Kim, S. *Org. Biomol. Chem.* **2013**, *11*, 6879. (c) Zhao, D.; Nimphius, C.; Lindale, M.; Glorius, F. *Org. Lett.* **2013**, *15*, 4504. (d) Park, S.; Seo, B.; Shin, S.; Son, J.-Y.; Lee, P. H. *Chem. Commun.* **2013**, *49*, 8671. (e) Ryu, T.; Kim, J.; Park, Y.; Kim, S.; Lee, P. H. *Org. Lett.* **2013**, *15*, 3986. (f) Park, Y.; Seo, J.; Park, S.; Yoo, E. J.; Lee, P. H. *Chem.—Eur. J.* **2013**, *19*, 16461. (g) Mo, J.; Lim, S.; Park, S.; Ryu, T.; Kim, S.; Lee, P. H. *RSC Adv.* **2013**, *3*, 18296. (h) Park, Y.; Jeon, I.; Shin, S.; Min, J.; Lee, P. H. *J. Org. Chem.* **2013**, *78*, 10209. For recent examples of C–H functionalization directed by sulfur-containing groups, see: (i) Qi, Z.; Wang, M.; Li, X. *Chem. Commun.* **2014**, *50*, 9776. (j) Wang, B.; Shen, C.; Yao, J.; Yin, H.; Zhang, Y. *Org. Lett.* **2014**, *16*, 46. (k) Dong, Y.; Liu, G. *Chem. Commun.* **2013**, *49*, 8066. (l) Zhang, X.-S.; Zhu, Q.-L.; Zhang, Y.-F.; Li, Y.-B.; Shi, Z.-J. *Chem. Eur. J.* **2013**, *19*, 11898. (m) Li, F.; Liu, T.-X.; Wang, G.-W. *Org. Lett.* **2012**, *14*, 2176. (n) Yu, M.; Xie, Y.; Xie, C.; Zhang, Y. *Org. Lett.* **2012**, *14*, 2164.

(6) For example, see: (a) Jarvis, A.; Whitwood, A. C.; Fairlamb, I. J. S. *Dalton Trans.* **2011**, *40*, 3695. (b) Kobatake, T.; Kondoh, A.; Yoshida, S.; Yorimitsu, H.; Oshima, K. *Chem.—Asian J.* **2008**, *3*, 1613. (c) Kondoh, A.; Yorimitsu, H.; Oshima, K. *J. Am. Chem. Soc.* **2007**, *129*, 6996. (d) Aucott, S. M.; Slawin, A. M. Z.; Woollins, J. D. *Polyhedron* **2003**, *22*, 361. (e) Ahmad, S.; Isab, A. A.; Perzanowski, H. P.; Hussain, M. S.; Akhtar, M. N. *Transition Met. Chem.* **2002**, *27*, 177.

(7) For example, see: (a) Shimizu, M.; Hirano, K.; Satoh, T.; Miura, M. *J. Org. Chem.* **2009**, *74*, 3478. (b) Uto, T.; Shimizu, M.; Ueura, K.; Tsurugi, H.; Satoh, T.; Miura, M. *J. Org. Chem.* **2008**, *73*, 298. (c) Umeda, N.; Tsurugi, H.; Satoh, T.; Miura, M. *Angew. Chem., Int. Ed.* **2008**, *47*, 4019.

(8) Nobushige, K.; Hirano, K.; Satoh, T.; Miura, M. *Org. Lett.* **2014**, *16*, 1188.

(9) (a) Schipper, D. J.; Hutchinson, M.; Fagnou, K. *J. Am. Chem. Soc.* **2010**, *132*, 6910. (b) Zhao, P.; Niu, R.; Wang, F.; Han, K.; Li, X. *Org. Lett.* **2012**, *14*, 4166. (c) Li, B.; Ma, J.; Liang, Y.; Wang, N.; Xu, S.; Song, H.; Wang, B. *Eur. J. Org. Chem.* **2013**, 1950. (d) Wang, F.; Qi, Z.; Sun, J.; Zhang, X.; Li, X. *Org. Lett.* **2013**, *15*, 6290. (e) Qian, Z.-C.; Zhou, J.; Li, B.; Hu, F.; Shi, B.-F. *Org. Biomol. Chem.* **2014**, *12*, 3594. (f) Liu, B.; Zhou, T.; Li, B.; Xu, S.; Song, H.; Wang, B. *Angew. Chem., Int. Ed.* **2014**, *53*, 4191. See also selected reviews for C–H bond cleavage/alkyne insertion: (g) Jia, C.; Kitamura, T.; Fujiwara, Y. *Acc. Chem. Res.* **2001**, *34*, 633. (h) Vasil'ev, A. V. *Russ. J. Org. Chem.* **2009**, *45*, 1. (i) Kitamura, T. *Eur. J. Org. Chem.* **2009**, 1111. (j) Nakao, Y. *Chem. Rec.* **2010**, *11*, 242. (k) de Mendoza, P.; Echavarren, A. M. *Pure Appl. Chem.* **2010**, *82*, 801.

(10) Saito, M.; Nishibayashi, Y.; Uemura, S. *Organometallics* **2004**, *23*, 4012.

(11) Bontemps, S.; Sircoglou, M.; Bouhadir, G.; Puschmann, H.; Howard, J. A. K.; Dyer, W. P.; Miqueu, K.; Bourissou, D. *Chem.—Eur. J.* **2008**, *14*, 731.

(12) Novak, Z.; Nemes, P.; Kotschy, A. *Org. Lett.* **2004**, *6*, 4917.

(13) Kropp, J. P.; Crawford, D. S. *J. Org. Chem.* **1994**, *59*, 3102.